Survivin as a potential target for cancer therapy

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 15, 2015, Pages 6187-6191

  Soleimanpour, Elaheh ^a   Babaei, Esmaeil ^a  

^a UNIVERSITY OF TABRIZ   (Iran)

Author keywords

Antiapoptotic protein; Apoptosis; Cancer; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR MARKER;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; GENE THERAPY; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; UPREGULATION;

APOPTOSIS; BIOMARKERS, TUMOR; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84944463143     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.15.6187     Document Type: Review

References (61)

1. Altieri DC (1994). Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem, 269, 3139-42.
2. Altieri DC (2008). Survivin, cancer networks and pathwaydirected drug discovery. Nat Rev Cancer, 8, 61-70.
3. Altieri DC (2013). Targeting surviving in cancer. Cancer Letters, 332, 225-8.
4. Asanuma K, Moriai R, Yajima T, et al (2000). Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res, 91, 1204-9.
5. Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD (2006). Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg, 41, 1431-40.
6. Babaei E, Mowla SJ, Shariat Torbaghan S, Emadi Baygi M (2006). Detection of surviving gene expression in formalinfixed paraffin-embedded tissue of human osteosarcoma: its potential usefulness in diagnosis and prognosis of bone tumors. IBJ, 10, 39-45.
7. Barrett RM, Osborne TP, Wheatley SP (2009). Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle, 8, 278-83.
8. Caldas H, Fangusaro JR, Boué DR, Holloway MP, Altura RA (2007). Dissecting the role of endothelial survivin δEx3 in angiogenesis. Blood, 109, 1479-89.
9. Carrasco RA, Stamm NB, Marcusson E, et al (2011). Antisense inhibition of surviving expression as a cancer therapeutic. Mol Cancer Ther, 10, 221-32.
10. Carter BZ, Mak DH, Schober WD, et al (2006). Regulation of survivin expression through Bcr-Abl/MAPK cascade: Targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood, 107, 1555-63.
11. Castro-Gamero AM, Borges KS, et al (2013). Tetra-Omethyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells. Invest New Drugs, 31, 858-70
12. Cheng Q, Ling X, Haller A, et al (2012). Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol, 3, 179-97.
13. Cheng Z, Hu L, Fu W, Zhang Q, Liao X (2007). Expression of survivin and its splice variants in gastric cancer. J Huazhong Univ Sci Technolog Med Sci, 27, 393-8.
14. Cheung CH, Sun X, Kanwar JR, et al (2010). A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF alpha therapy. Cancer Cell Int, 10.
15. Colnaghi R, Wheatley SP (2010). Liaisons between survivin and Plk1 during cell division and cell death. J Biol Chem, 285, 22592-604.
16. Coumar M, Tsai F, Kanwar JR, Sarvagalla S, Cheung CH (2013). Treat cancers by targeting survivin: Just a dream or future reality? Cancer Treatment Reviews, 39, 802-11.
17. Croci DO, Cogno IS, Vittar NB, et al (2008). Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem, 105, 381-90.
18. Fisker N, Westergaard M, Hansen HF, Hansen JB (2007). Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Nucleosides Nucleotides Nucleic Acids, 26, 1427-30.
19. Hansen JB, Fisker N, Westergaard M, et al (2008). SPC3042: a proapoptotic surviving inhibitor. Mol Cancer Ther, 7, 2736-45.
20. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA (2004). Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem, 279, 40511-20
21. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW (2001). Effects of surviving antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst, 93, 1541-52.
22. Kanwar JR, Kamalapuram SK, Kanwar RK (2013). Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev, 33, 765-89.
23. Kyani K, Babaei E, Hosseinpour Feizi MA, et al (2014). Detection of surviving 2a gene expression in thyroid nodules. J Cancer Res Ther, 10, 312-6.
24. Lens SM, Vader G, Medema RH (2006). The case for survivin as mitotic regulator. Curr Opin Cell Biol, 18, 616-22.
25. Li F, Ambrosini G, Chu EY, et al (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396, 580-4.
26. Li F (2014). Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer? Am J Cancer Res, 4, 304-11.
27. Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F (2010). Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res, 29, 8.
28. Ling X, Cao SS, QY, et al (2012). A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner shows superior antitumor activity. PLoS One, 7.
29. Liu JL, Wang Y, Jiang J, et al (2010). Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA. Chin Med J, 123, 2901-7.
30. Mesri M, Wall NR, Li J, Kim RW, Altieri DC (2001). Cancer gene therapy using a surviving mutant adenovirus. J Clin Invest, 108, 981-90.
31. Mirza A, McGuirk M, Hockenberry TN, et al (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene, 21, 2613-22.
32. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008). Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res, 14, 5000-5.
33. Mobahat M, Narendran A, Riabowol K (2014). Survivin as a preferential target for cancer therapy. Int J Mol Sci, 15, 2494-516.
34. Mohamed S, Yasufuku K, Nakajima T, et al (2009). Nuclear survivin in pN2 nonsmall cell lung cancer: Prognostic and clinical implications. Eur Respir J, 33, 127-33.
35. Na YS, Yang SJ, Kim SM, et al (2012). YM155 induces EGFR suppression in pancreatic cancer cell. PLoS ONE, 7, 38625.
36. Nakahara T, Kita A, Yamanaka K, et al (2012). Broad spectrum and potent antitumor activities of YM155, a novel smallmolecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci, 102, 614-21.
37. Nouraee N, Mowla SJ, Ozhand A, et al (2009). Expression of Survivin and Its Spliced Variants in Bladder Tumors as a Potential Prognostic Marker. Urol J, 6, 101-8.
38. O'Connor DS, Grossman D, Plescia J, et al (2000). Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Nat Acad Sci, 97, 13103-7.
39. Olie RA, Simoes-Wust AP, Baumann B, et al (2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res, 60, 2805-9.
40. Ouyang L, Shi Z, Zhao S, et al (2012). Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif, 45, 487-98.
41. Pavlyukov MS, Antipova NV, Balashova MV, et al (2011). Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem, 286, 23296-307.
42. Pennati M, Binda M, Colella G, et al (2003). Radiosensitizationof human melanoma cells by ribozyme-mediated inhibition of surviving expression. J Invest Dermatol, 120, 648-54.
43. Plescia J, Salz W, Xia F, et al (2005). Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 7, 457-68.
44. Poomsawat S, Punyasingh J, Vejchapipat P (2014). Overexpression of survivin and caspase 3 in oral carcinogenesis. Appl Immunohistochem Mol Morphol, 22, 65-71.
45. Rodel C, Haas J, Groth A, et al (2003). Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys, 55, 1341-7.
46. Sah NK, Munshi A, Hobbs M, et al (2006). Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys, 66, 852-9.
47. Shariat SF, Casella R, Khoddami SM, et al (2004). Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol, 171, 626-30.
48. Sharma H, Sen S, Lo Muzio L, Mariggio A, Singh N (2005). Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther, 4, 720-7.
49. Shin S, Sung BJ, Cho YS, et al (2001). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry, 40, 1117-23.
50. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C (2003). Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene, 22, 4266-80.
51. Sung B-J, Cho Y-S, Kim H-J, et al (2001). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry, 40, 1117-23.
52. Tamm I, Wang Y, Sausville E, et al (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res, 58, 5315-20
53. Tran J, Master Z, Yu JL, et al (2002). A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A, 99, 4349-54.
54. Tu SP, Jiang XH, Lin MC, et al (2003). Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res, 63, 7724-32.
55. Vandghanooni S, Eskandani M, Montazeri V, et al (2011). Survivin-delta Ex3: a novel biomarker for diagnosis of papillary thyroid carcinoma. J cancer Res Ther, 7, 325-30.
56. Yamamoto T, Manome Y, Nakamura M, Tanigawa N (2002). Downregulation of surviving expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer, 38, 2316-24.
57. Yamashita SI, Masuda Y, Kurizaki T, et al (2007). Survivin expression predicts early recurrencein early-stage breast cancer. Anticancer Res, 27, 2803-8.
58. Yong-Gang Lv, Fang Yu, Qing Yao, Jiang-Hao Chen, Ling Wang (2010). The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis, 2, 100-10.
59. You L, He B, Xu Z, et al (2004). InhibitionofWnt-2-mediated signaling induces programmed cell death in nonsmall-cell lung cancer cells. Oncogene, 23, 6170-74.
60. Zhang MC, Hu CP, Chen Q (2006). Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells. Zhonghua Zhong Liu Za Zhi, 28, 408-12.
61. Ziaee SA, Moula SJ, Hosseini Moghaddam SM, Eskandar-Shiri D (2006). Diagnosis of bladder cancer by urine survivin, an inhibitor of apoptosis. Urol J, 3, 150-3.